Cytokeratin-positive interstitial reticulum cell (CIRC) tumor in the lymph node: a case report of the transformation from the epithelioid cell type to the spindle cell type

Sachiko Kaji 1*, Nobuyuki Hiruta 2, Daisuke Sasai 3, Makoto Nagashima 4, Rintaro Ohe 5 and Mitsunori Yamakawa 5

Abstract
Background: Cytokeratin-positive interstitial reticulum cells (CIRCs), which are a subgroup of fibroblastic reticular cells (FRCs), are known to be present in the lymph nodes. There have been only a few cases of tumors derived from CIRCs.

Case presentation: We have reported a new case involving a CIRC tumor in a 75-year-old man and reviewed the literature. The resected mediastinal lymph nodes showed epithelial-like proliferation of large atypical round and polygonal epithelioid cells. The tumor cells expressed CK8, CK18, CAM5.2, AE1/AE3, epithelial membrane antigen, vimentin, fascin, and some FRC markers, which is consistent with the diagnosis of a CIRC tumor. Following chemotherapy, the CIRC tumor was observed to have responded very well and became difficult to confirm on imaging, but a small cell lung carcinoma developed 12 months later. Chemoradiotherapy was performed, but the patient passed away 29 months after the initial diagnosis. The autopsy revealed the recurrence of the CIRC tumor, residual small cell lung carcinoma, and a very small latent carcinoma of the prostate. The relapsed CIRC tumor cells had a spindle shape; they were highly pleomorphic and had invaded the superior vena cava.

Conclusion: We first reported autopsy findings of CIRC tumors and demonstrated the transformation of the tumor from the epithelioid cell type to the spindle cell type.

Keywords: Cytokeratin-positive interstitial reticulum cells, Fibroblastic reticular cells, Cell morphology, Transform, Autopsy

Background
Lymph node structure and function are supported by dendritic/reticular cells, which are divided into three subtypes: follicular dendritic cells (FDCs), interdigitating dendritic cells (IDCs), and fibroblastic reticular cells/interstitial reticulum cells (FRCs). FRCs are located in the parafollicular and deep cortex areas and comprise a mesh-like reticular network with reticular fibers and fibrous extracellular matrix bundles [1–6]. FRCs are embedded in the extracellular matrix [7] and are in contact with immune cells [3]. A subgroup of FRCs that can express cytokeratins are called cytokeratin-positive interstitial reticulum cells (CIRCs). CIRC tumors are considered a subset of FRC tumors.

CIRC tumors are difficult to diagnose because of their nature. The expression pattern of CIRC tumors is a challenge for pathologists, as several neoplasms express cytokeratins and vimentin, which can result in confusion. It

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
is important to distinguish metastatic carcinoma, Hodgkin lymphoma, FDC sarcoma, and IDC sarcoma. Very few reports of cases of CIRC tumors have been published [8–14]; among these cases, only two had a fatal clinical outcome [9, 11]. To the best of our knowledge, this is the first report of a case of a CIRC tumor with autopsy findings. The autopsy provided evidence of the biological behavior of the CIRC tumor.

We first report here a new case involving a CIRC tumor in a 75-year-old man and transformation of the tumor from the epithelioid cell type of a primary lymph node tumor to the spindle cell type of a recurrent tumor on autopsy. The present study has provided specific immunohistochemical findings as well as electron microscopy findings for this tumor; in addition, we have reviewed the literature.

**Case presentation**

**Clinical presentation**

A 75-year-old Japanese man was found to have mediastinal lymphadenopathy by computed tomography (Fig. 1a, b). Transbronchial aspiration cytology was performed at the Sakura Medical Center, Toho University. The cytological diagnosis confirmed that it was a malignant tumor with the possibility of it being a lymphoreticular tumor or a metastatic carcinoma. Three months later, a lymphadenectomy was performed. The histological findings suggested that the tumor was a malignant lymphoma and was most likely Hodgkin lymphoma or a metastatic carcinoma. Immunohistochemically, the tumor cells expressed cytokeratins and vimentin and were negative for lymphoid markers. These findings suggested that the tumor was likely a metastatic carcinoma. However, positron emission tomography/computed tomography showed no other lesions throughout the body except for swollen mediastinal lymph nodes (Fig. 1c, d), and gastrointestinal endoscopic examinations revealed no other abnormalities. The levels of serum tumor markers, including carcinoembryonic antigen, carbohydrate antigen 19–9, squamous cell carcinoma antigen, neuron specific enolase (NSE), progastrin-releasing peptide, and cytokeratin 19 fragment, were within the normal ranges. The serum soluble interleukin-2 receptor level was not at a high level (469 U/ml). Based on this result, a CIRC tumor was suspected.

The CIRC tumor responded very well to chemotherapy and became difficult to confirm on imaging, but 12 months later, a new tumor was detected in the hilar region of the right lung on computed tomography. A small cell carcinoma was diagnosed by transbronchial aspiration cytology. The patient underwent chemoradiotherapy, but he later presented with superior vena cava syndrome and passed away. The total clinical course lasted for 29 months.

**Fig. 1** Enhanced computed tomography revealed swelling of the right upper paratracheal lymph node (a, arrow) and right lower paratracheal lymph node (b, arrow). Abnormally high uptake in the right supravacular lymph node (c, arrowhead) and right lower paratracheal lymph node (d, arrowheads) was detected by positron emission tomography/computed tomography. The right lower paratracheal lymph node was the main lesion, which was approximately 2.7 cm in size. The right upper paratracheal lymph node and right supravacular lymph node were metastatic lesions and showed slight swelling.
Pathological findings

**Lymph node findings**

The completely excised mediastinal lymph node measured approximately 2.7 × 2.0 × 2.1 cm. On microscopic evaluation, the nodal architecture was mostly preserved, except in areas where neoplastic proliferation caused partial effacement (Fig. 2a). The lymph node was inconspicuously demarcated by fibrous tissue continuing to the capsule. Circumferential tumor cell proliferation around the follicles was conspicuous (Fig. 2a, b). Tumor cells were highly atypical, large in size, and round or polygonal in shape. Most of the tumor cells had round vesicular nuclei and prominent nucleoli. The abundant cytoplasm was pale to eosinophilic, with an ill-defined cell border resulting in an epithelioid-like appearance (Fig. 2b). The tumor cells were admixed with many small lymphocytes, plasma cells, and eosinophils. Tumor cells that resembled Hodgkin’s cells and Reed–Sternberg cells were scattered throughout the tumor. Typical and atypical mitoses were frequent (20/10 high-power fields). Apoptotic cells were also noted. Delicate collagen fibers often intermingled with tumor cells. The tumor cells and collagen fibers were closely associated. The cytoplasm of some tumor cells was hyalinized and appeared to continue to form collagen fibers. The tumor cells were often elongated in areas of increased numbers of collagen fibers. Necrotic foci and hemorrhage were not observed. Metastases of two small mediastinal lymph nodes were recognized.

The tumor cells were immunohistochemically positive for cytokeratin (CK)7, CK8, CK18, CAM5.2, AE1/AE3, epithelial membrane antigen (EMA), vimentin, fascin, l-caldesmon, prolyl 4-hydroxylase 1, lysyl hydroxylase 3, and transglutaminase II (Table 1, Fig. 3). Immunoreaction with cytokeratins revealed fine cytoplasmic projections and reticular patterns in the tumor cells. Immunohistochemical staining of tenascin-C, prolyl 3-hydroxylase 1, alpha smooth muscle actin (α-SMA), desmin, FDC markers (CD23, D2–40, clusterin, CNA.42, low affinity NGFR, CD21, and CD35) and histiocytic/dendritic cell markers (CD1a, CD11c, langerin, DC-SIGN, DC-LAMP, CD83, DEC205, S-100 protein, CD68, and Factor XIIIa) were negative. In addition, the staining of other lymphocyte markers, including CD3, CD4, CD5, CD8, CD20, CD30, CD45, CD45RO, CD79a, and PAX5, were all negative. Staining of markers important for distinguishing metastatic tumors (34βE12, prostate-specific antigen, NKX3.1, P504S, polyclonal carinoembryonic antigen, CK5/6, CK20, TTF-1, Napsin A, p63, p40, Melan A, HMB45, CD34, CD117, and ALK) were negative. Staining of neuroendocrine markers (NSE, chromogranin A, synaptophysin, and CD56) were also negative. Detection of Epstein-Barr encoding region (EBER)-1 was negative by in situ hybridization (ISH). Less than 10% of the tumor cells showed weak expression of EGFR. Up to 95% of the tumor cells showed high expression of the p53 protein. The Ki-67 labeling index (LI) was high (greater than 75%).

The ultrastructure of the tumor cells showed large cells with occasional indented nuclei with vesicular chromatin. The cytoplasm of the cells contained intermediate filaments. Some tumor cells exhibited dendritic interdigitating cytoplasmic processes and desmosome-like junctions (Fig. 4). The tumor cells, however, had no endocrine granules.

**Autopsy findings**

A relapsed CIRC tumor was located that extended from the apex of the right lung to the clavicle fossa. It had progressed to the superior vena cava (Fig. 5a) and was partially obstructing it. The patient presented with superior vena cava syndrome, which was the cause of his death. Histologically, changes in tumor cell morphology were observed, resulting in the formation of spindle cells that formed loose fascicles (Fig. 5b). The tumor cells showed extremely advanced pleomorphism in the relapsed tumor compared with that in the primary tumor, with numerous bizarre large and multinucleated cells.
| Antibody          | CIRC tumor | Relapsed tumor | Small cell carcinoma |
|-------------------|------------|----------------|----------------------|
|                   | Primary tumor |               |                      |
| **Epithelial markers** |            |                |                      |
| CK7               | +          | −              | −                    |
| CK8               | +          | +              | ±                    |
| CK18              | +          | +              | ±(weakly)            |
| CAM5.2            | +          | +              | ±                    |
| AE1/AE3           | +          | +              | ±                    |
| EMA               | +          | +              | ±                    |
| 34βE12            | −          | −              | −                    |
| PSA               | −          | −              | −                    |
| NKX3.1            | −          | −              | −                    |
| PS045             | −          | −              | −                    |
| pCEA              | −          | −              | −                    |
| CK5/6             | −          | −              | −                    |
| CK20              | −          | −              | −                    |
| TTF-1             | −          | −              | ±(weakly)            |
| Napsin A          | −          | −              | −                    |
| p63               | −          | −              | −                    |
| p40               | −          | −              | −                    |
| **Neuroendocrine cell markers** |            |                |                      |
| NSE               | −          | −              | +                    |
| Chromogranin A    | −          | −              | ±                    |
| Synaptophysin     | −          | −              | +                    |
| CD56              | −          | −              | +                    |
| **Lymphoid markers** |            |                |                      |
| CD3               | −          | −              | −                    |
| CD4               | −          | −              | −                    |
| CD5               | −          | −              | −                    |
| CD8               | −          | −              | −                    |
| CD20              | −          | −              | −                    |
| CD30 (Ki-1)       | −          | −              | −                    |
| CD45 (LCA)        | −          | −              | −                    |
| CD45RO (UCHL-1)   | −          | −              | −                    |
| CD79a             | −          | −              | −                    |
| PAX5              | −          | −              | −                    |
| EBER-1*           | −          | −              | −                    |
| **FRC markers**   |            |                |                      |
| Tenascin-C        | −          | −              | −                    |
| Prolyl 3-hydroxylase 1 | −      | −              | −                    |
| l-caldesmon       | +          | +              | −                    |
| Prolyl 4-hydroxylase 1 | +      | +              | −                    |
| Lysyl hydroxylase 3 | +        | +              | −                    |
| Transglutaminase II | +        | +              | −                    |
and many typical and atypical mitoses (42/10 high-power fields). The atypical large cells showed greater increases in size and atypia in the relapsed tumor than in the primary tumor. The tumor cells were mixed with delicate collagen fibers. A massive area (approximately 80%) of necrosis was observed. The CIRC tumor had also metastasized to the right paratracheal lymph node.

The tumor cells of relapsed CIRC tumors were positive for CK8, CK18, CAM5.2, AE1/AE3, EMA, vimentin, fascin, l-caldesmon, prolyl 4-hydroxylase 1, lysyl hydroxylase 3, and transglutaminase II, indicating the presence of a CIRC tumor (Table 1, Fig. 3). Immunoreaction with cytokeratins showed dendritic staining patterns in tumor cells. In contrast to the primary lesion, the relapsed tumor was negative for CK7. The relapsed tumor cells were negative for NSE, chromogranin A, synaptophysin, CD56, Napsin A and ALK. They were also negative for prostate-specific antigen, NKX3.1 and P504S, thus ruling

Table 1 Immunophenotypes of CIRC tumor and small cell carcinoma of this case (Continued)

| Antibody             | Immunochemistry                        | CIRC tumor Primary tumor | Relapsed tumor | Small cell carcinoma |
|----------------------|----------------------------------------|--------------------------|               |                      |
| α-SMA                | –                                      | –                        | –             | –                     |
| **FDC markers**      |                                        |                          |               |                      |
| CD23                 | –                                      | –                        | –             | –                     |
| D2-40                | –                                      | –                        | –             | –                     |
| Clusterin            | –                                      | –                        | –             | –                     |
| CNA.42               | –                                      | –                        | –             | –                     |
| NGFR, low affinity   | –                                      | –                        | –             | –                     |
| CD21                 | –                                      | –                        | –             | –                     |
| CD35                 | –                                      | –                        | –             | –                     |
| **Histiocytic/dendritic cell markers** |                                        |                          |               |                      |
| CD1a                 | –                                      | –                        | –             | –                     |
| CD11c                | –                                      | –                        | –             | –                     |
| Langerin             | –                                      | –                        | –             | –                     |
| DC-SIGN              | –                                      | –                        | –             | –                     |
| DC-LAMP              | –                                      | –                        | –             | –                     |
| CD83                 | –                                      | –                        | –             | –                     |
| DEC205               | –                                      | –                        | –             | –                     |
| S-100                | –                                      | –                        | –             | –                     |
| CD68                 | –                                      | –                        | –             | –                     |
| Fascin               | +                                      | –                        | –             | –                     |
| Factor XIIIa         | –                                      | –                        | –             | –                     |
| **Others**           |                                        |                          |               |                      |
| Melan A              | –                                      | –                        | –             | –                     |
| HMB45                | –                                      | –                        | –             | –                     |
| Desmin               | –                                      | –                        | –             | –                     |
| Vimentin             | +                                      | +                        | –             | –                     |
| CD34                 | –                                      | –                        | –             | –                     |
| CD117                | –                                      | –                        | –             | –                     |
| ALK                  | –                                      | –                        | –             | –                     |
| EGFR                 | < 10%                                  | 20%                      | –             | –                     |
| p53                  | 95%                                    | 80%                      | –             | –                     |
| K-Ras (hot spot)     | > 75%                                  | 15%                      | < 50%         | –                     |

- negative, ± partially positive, + diffusely positive, PSA Prostate-specific antigen, NGFR Nerve growth factor receptor, FRC Fibroblastic reticular cell, FDC Follicular dendritic cell, EBER-1 (in situ hybridization) Epstein-Barr virus-encoded small RNA-1, ALK Anaplastic lymphoma kinase, EGFR Epidermal growth factor receptor
Fig. 3 (See legend on next page.)
The tumor cells were diffuse and remained within the prostate. There was no lymphatic sponded to a Gleason pattern of 3 + 4, and it had left lobe of the prostate. The adenocarcinoma corre-

Region, but there was no clear continuity between them. The small cell carcinoma and the CIRC tumor were located somewhat close to each other in the hilar node. The small cell lung carcinoma were negative for chromogranin A and strongly positive for synaptophysin and CD56. Tumor cells of primary CIRC tumors and relapsed CIRC tumors were positive for I-caldesmon, prolyl 4-hydroxylase 1 and transglutaminase II. Tumor cells of small cell lung carcinoma were focally positive for synaptophysin, and strongly positive for TTF-1.

The maximum size was observed for a relapsed tumor. The tumors ranged in size from 0.9 to 9 cm. The Ki-67 LI was very low (15%).

A small cell carcinoma had formed in the hilar region of the right lung. Histologically, the tumor cells showed the typical finding, which is completely different from the morphology of CIRC tumors (Fig. 5c). Furthermore, immunohistochemical staining of TTF-1 and neuroendocrine cell markers (NSE, chromogranin A, synapto-

physin, and CD56) were positive to varying degrees (Fig. 3). Immunohistochemical staining was negative for FRC markers, which are useful for diagnosing CIRC tumors (Fig. 3). Staining of Napsin A, ALK, and EGFR were negative. The tumor metastasized to the liver, left paratracheal lymph node, and tracheal bifurcation lymph node. The small cell carcinoma and the CIRC tumor were located somewhat close to each other in the hilar region, but there was no clear continuity between them.

In addition, a small adenocarcinoma was found in the left lobe of the prostate. The adenocarcinoma corre-

sponded to a Gleason pattern of 3 + 4, and it had remained within the prostate. There was no lymphatic or vascular invasion. The tumor cells were diffuse and strongly positive for prostate-specific antigen, and the focal cells were weakly positive for NKX3.1.

Discussion and conclusion

The first report of CIRCs in normal lymph nodes was published in 1987 by Franke and Moll [15]. CIRCs are a subset of FRCs that express vimentin as well as CK8 and CK18 [15–17], Alpha-SMA is expressed in 20–60% of CIRCs, whereas desmin is expressed in 1–10% of CIRCs [8, 16]. CIRCs have elongated cell processes and are found in the extrafollicular compartment of the outer and inner cortex along blood vessels. They have also been observed in the spleen and tonsils. Electron microscopy has confirmed the presence of abundant intermediate filaments and tonofilament-like tight bundles in CIRCs. Since Gould et al. first reported on CIRC-derived tumors in 1990, to the best of our knowledge, only seven relevant articles have been published in English [8–14]. A total of 12 cases have been dia-

nosed as CIRC tumors, including our case. Although one case was reported to involve an FRC tumor, the tumor re-
curred and morphed into a CIRC tumor [11]. Table 2 summar-

izes the clinical data of published CIRC cases. The age of the patients in these reports ranged from 21 to 75 years, and the subjects were predominantly male. Half of the cases in-

volved tumors that were localized in the hilum and mediastinal lymph node. Tumors ranged in size from 0.9 to 9 cm. The maximum size was observed for a relapsed tumor. The histopathological findings were variable, but on the basis of morphological features, the published cases were divided into three types. The initial type mainly involved spindle cells that formed fascicles, and the storiform pattern often predominated. As a result, the tumor in this type gave the impression of a noncohesive and reticular lesion. The second type mainly involved nests of round or oval cells, and a vaguely nodular pattern predominated. The tumor may also have had a cohesive and epithelioid-like appearance. The third type involved the admixture of the two aforementioned pat-
bersons; therefore, the proliferative pattern was mixed and variable. All three types had the common feature of involving tumor cells that were mixed with numerous lymphocytes, granulocytes, and plasma cells. Occasionally, multinucleated tumor cells and large or giant tumor cells were admixed. Accor-
ding to previously reported cases, the spindle cell type is less frequently observed than the other two types. In the

Fig. 3 Immunohistochemical staining of primary cytokeratin-positive interstitial reticulum cell (CIRC) tumors, relapsed CIRC tumors and small cell lung carcinoma using CAM5.2, AE1/AE3, TTF-1, chromogranin A, synaptophysin, CD56, I-caldesmon, prolyl 4-hydroxylase 1 and transglutaminase II antibodies. Tumor cells of primary CIRC tumors and relapsed CIRC tumors were positive for CAM5.2 and AE1/AE3 and negative for TTF-1. Tumor cells of small cell lung carcinoma were focally positive for CAM5.2 and AE1/AE3 and weakly positive for TTF-1. Tumor cells of primary CIRC tumors and relapsed CIRC tumors were negative for chromogranin A, synaptophysin and CD56. Tumor cells of small cell lung carcinoma were focally positive for synaptophysin and strongly positive for TTF-1. Tumor cells of primary CIRC tumors and relapsed CIRC tumors were positive for I-caldesmon, prolyl 4-hydroxylase 1 and transglutaminase II. Tumor cells of small cell lung carcinoma were negative for I-caldesmon, prolyl 4-hydroxylase 1 and transglutaminase II.
present case report, the primary tumor showed a round or oval cell (epithelioid cell) type, but the recurrent tumor morphed into the spindle cell type, indicating the transformability of neoplastic cells.

The immunohistochemical profile of the 12 CIRC tumor cases is summarized in Table 3. All CIRC tumor cases were positive for epithelial markers, such as CAM5.2 (CK8), CK18, AE1/AE3 and EMA, and vimentin. The expression of desmin and α-SMA was variable. Two cases showed aberrant expression of S-100 protein and CD68 [10, 13, 14]. As a rule, staining of FDC markers, including CD21 and CD35, were negative. Only one case, which was reported as involving a CIRC tumor with features of FDCs, showed weak CD21 positivity [13]. In the present case, tumor cells coexpressed cytokeratins and vimentin, and they were positive for some FRC markers, including prolyl 4-hydroxylase 1, lysyl hydroxylase 3 and transglutaminase II [18, 19]. Chemotherapy and autopsy-related artifacts could be responsible for the differences in the morphologies of the tumors. In fact, there was a decrease in the Ki-67 LI of the relapsed tumor compared with that of the primary tumor. This suggested that the chemotherapy effect and autopsy-related artifacts occurred, because the autopsy sample showed 80% necrosis. Electron microscopy analysis was performed in nine cases, including our case, and in all cases, the tumors demonstrated some epithelial cell features, such as tonofilaments, desmosomes, and desmosome-like junctions. Tonofilaments are a feature of normal CIRCs. In fact, Gould et al. suggested that CIRCs show increased epithelial differentiation, including the formation of desmosomes, as they become neoplastic [8].

CIRC tumors exhibit a wide spectrum of clinical behavior, which can result in outcomes that range from good to poor. Currently, there is no fixed treatment method for CIRC tumors. Surgical resection, chemotherapy, and radiotherapy are conducted, sometimes in combination. Including the present patient, three patients have died of the disease. The survival period ranged from 9 to 29 months after the initial diagnosis (Table 2).

The differential diagnoses, including FDC sarcoma, IDC sarcoma, and metastatic carcinoma, are important. Binucleated or multinucleated tumor cells are often seen in FDC sarcoma that are similar to those in CIRC tumors. The distribution pattern of tumor cells in lymph nodes and the absence of collagen fibers mixed with tumor cells in FDC sarcoma are findings that are different from those in CIRC tumors. Similar to CIRC tumors, IDC sarcoma tumor cells present in a paracortical distribution with residual follicles. Unlike CIRC tumors, IDC sarcoma does not present with interspersed delicate collagen fibers intermingled with tumor cells. Usually, in metastatic carcinoma, there is no diffuse spreading of small lymphocytes, plasma cells or eosinophils throughout the tumor,
and the cell border is clear. Metastatic carcinoma presents in the lymph node without the preservation of follicles. The nuclei of the CIRC tumor are more highly vesicular and show more finely dispersed chromatin and a thinner nuclear membrane than metastatic carcinoma cells. However, the histological appearance of CIRC tumors is sometimes indistinguishable from that of FDC sarcoma, IDC sarcoma, and metastatic carcinoma. Therefore, immunophenotyping of markers, such as CD21 and S-100 protein, is necessary for precise diagnosis. In the case of metastatic carcinoma, it is essential to investigate primary lesions. In our case, findings similar to those of Hodgkin lymphoma were found in the primary tumor, and differentiation was required. Compared with that in Hodgkin lymphoma, in CIRC tumors, the number of large tumor cells is much higher than that of lymphocytes. The tumor cells tend to proliferate, which preserved the lymphoid follicle, and this was not observed in Hodgkin lymphoma. Ultimately, the

| Case No. | Diagnosis | Complication (malignancy) | Age | Sex | Nodal / Extranodal Region | Size | Treatment | Outcome | References |
|----------|-----------|---------------------------|-----|-----|----------------------------|------|-----------|---------|------------|
| 1        | CIRC tumor| Nodal                     | 57  | M   | Left hilum                 | NA   | A left thoracotomy          | Alive and well; 9 years | Eur J Cancer 1990; 26: 1121–6 |
| 2        | CIRC tumor| Nodal                     | 44  | M   | Left hilum                 | 4 cm | A left thoracotomy          | Alive and well; over 3 years | |
| 3        | CIRC tumor| Nodal                     | 61  | M   | Right hilum                | NA   | A right thoracotomy         | Alive and well; 13 months | |
| 4        | CIRC tumor| Nodal                     | 21  | F   | Mediastinal (superior)     | 2.5 cm | CHOP chemotherapy, Radiotherapy; 21 Gy VP-16 and CBDCA chemotherapy | Died of disease, 9 months | Am J Surg Pathol 2000; 24: 107–16 |
| 5        | CIRC tumor| Extranodal                | 73  | F   | Right proximal forearm     | NA   | Surgery (excision)          | NA | |
| 6        | CIRC tumor| Nodal                     | 62  | M   | Mediastinal (posterior)    | 7.4 cm | Radiotherapy; 65 Gy | NA | Histopathology 2003; 43: 491–4 |
| 7        | CIRC tumor| Nodal                     | 66  | M   | Submandibular              | 1.5 cm | Surgery (excision)          | Alive and well; 12 months | |
| 8        | FRC tumor (primary) | Nodal   | 70  | F   | Right submandibular       | 3.0 cm | Surgery | Died of disease, 10 months | Histopathology 2003; 43: 583–91 |
| CIRC tumor (relapse) | Nodal | Local relapse | 9.0 cm | VACOP B chemotherapy | Two cycles of CNOP chemotherapy | |
| 9        | CIRC tumor | Rectal adenocarcinoma | 62  | M   | Extranodal                 | 0.9 cm | Surgery (low anterior resection, splenectomy) | Alive and well; 2 years | Int J Surg Pathol 2014; 22: 447–50 |
| 10       | CIRC tumor with FDC features | Nodal | 54  | F   | Right axillary             | NA   | Surgery (excision)          | Alive and well; 2.5 years | Am J Surg Pathol 2015; 39: 573–80 |
| 11       | CIRC tumor | Uterine endometrioid carcinoma | 67  | F   | Pelvic                     | 3.5 cm | Surgery (hysterectomy, bilateral adnexectomy, pelvic lymphadenectomy) | Alive and well; 9 months | Hum Pathol 2016; 49: 15–21 |
| 12       | Current case (primary) | Nodal | 75  | M   | Mediastinal (superior)     | 2.7 cm | Surgery (excision)          | Died of disease, 29 months | |
| Current case (relapse) | Extranodal | Right lung apex to the clavicle fossa | 1.5 cm | CBDCA and DOC chemotherapy | |

CIRC Cytokeratin-positive interstitial reticulum cell, FRC Fibroblastic reticular cell, FDC Follicular dendritic cell, CHOP Cyclophosphamide, doxorubicin, vincristine, and prednisone, VP-16 Etoposide, CBDCA Carboplatin, VACOP-B Etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin, CNOP Cyclophosphamide, mitoxantrone, vincristin, and prednisone, DOC Docetaxel, CDDP Cisplatin, NGT Nogitecan, NA Not available
CIRC tumor was distinguished from Hodgkin lymphoma based on the immunostaining results. In contrast, careful examination was required because the patient suffered from small cell lung carcinoma after the onset of the CIRC tumor. Hematoxylin-eosin staining showed that the cell morphology of the CIRC tumor and small cell carcinoma were clearly different. However, evolution of small cell carcinoma towards sarcomatoid tumors following therapy must be distinguished from recurrent CIRC tumors with caution. Because CIRC tumors are similar to small cell lung carcinomas and express epithelial markers such as cytokeratin, more detailed examination using immunohistochemical and ultrastructural analysis is essential for differential diagnosis. Immunohistochemically, CIRC tumor cells showed positivity for FRC markers and negativity for neuroendocrine markers, whereas small cell lung carcinoma shows the opposite staining pattern. Ultrastructurally, CIRC tumor cells had no endocrine granules, and dendritic interdigitating cytoplasmic processes were rarely observed.

The pathogenesis of CIRC tumors is unknown; however, CIRCs grow from various reactive and inflammatory neoplastic lymphadenopathies and show an atypical appearance in human immunodeficiency virus-associated lymphadenopathy [20]. Little data are available on the expression of p53 in dendritic cell tumors [21–23]. Chan et al. suggested a role for p53 in the malignant transformation of dendritic cells in Castleman disease associated with FDC sarcoma. Although the relationship between CIRC tumors and p53 expression is unclear, Lucioni et al. reported increased p53 expression in relapsed tumors [11].

In conclusion, we first demonstrated here the transformation of CIRC tumor morphology from an epithelioid cell type to a spindle cell type and compared the primary lymph node lesion and the recurrent lesion on autopsy.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s13000-020-01032-9.

**Additional file 1** Fig. A. Histology of prostatic adenocarcinoma at autopsy. The tumor cells formed irregular small glands with small nests. The tumor margin is indicated by arrows. Fig. B. Immunohistochemical staining of small cell lung carcinoma using the p53 antibody. The tumor cells showed no positive staining in the nuclei. Fig. C. Immunohistochemical staining of colon carcinoma using the p53 antibody as a control. In contrast to small cell carcinoma, colon carcinoma showed positive staining in the nuclei.

**Abbreviations**

FDC: Follicular dendritic cell; IDC: Interdigitating dendritic cell; FRC: Fibroblastic reticular cell; CIRC: Cytokeratin-positive interstitial reticulum cell; CK: Cytokeratin; EMA: Epithelial membrane antigen; α-SMA: Alpha smooth muscle actin; EBV: Epstein-Barr virus; LI: Labeling index

**Acknowledgments**

The authors wish to thank Professor of Takayuki Nojima for his invaluable support and all the members of the Department of Surgical Pathology at Toho University Sakura Medical Center.

**Authors’ contributions**

Data preparation, KS, KN, SD, NW, OR, YM; original draft preparation and writing, KS; draft review and editing, OR, YM. All authors read and approved the final manuscript.

**Funding**

None.

**Availability of data and materials**

The data and materials are available upon request from the corresponding author.
Ethics approval and consent to participate
This study was approved by the Research Ethics Committee of Toho University Sakura Medical Center (S19080) and was performed in accordance with the Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Diagnostic Pathology, Chiba Kaighin Municipal Hospital, 3-31-1 Isobe, Mihama-ku, Chiba 261-0012, Japan. 2Department of Surgical Pathology, Toho University Sakura Medical Center, Sakura, Japan. 3Department of Pathology, Seirei Sakura Citizen Hospital, Sakura, Japan. 4Department of Surgery, Toho University Sakura Medical Center, Sakura, Japan. 5Department of Pathological Diagnostics, Yamagata University Faculty of Medicine, Yamagata, Japan.

Received: 20 April 2020 Accepted: 9 September 2020
Published online: 26 September 2020

References
1. von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nat Rev Immunol. 2003;3:867–78.
2. Gre tz JE, Kaldjian EP, Anderson AO, Shaw S. Sophisticated strategies for information encounter in the lymph node: the reticular network as a conduit of soluble information and a highway for cell traffic. J Immunol (Baltimore, Md: 1950). 1996;157:495–9.
3. Gre tz JE, Anderson AO, Shaw S. Cords, channels, corridors and conduits: critical architectural elements facilitating cell interactions in the lymph node cortex. Immunol Rev. 1997;156:11–24.
4. Kaldjian EP, Gre tz JE, Anderson AO, Proudfoot AE, Shaw S. Lymph-borne chemokines and other low molecular weight molecules reach high endothelial venules via specialized conduits while a functional barrier limits access to the lymphocyte microenvironments in lymph node cortex. J Exp Med. 2000;192:425–40.
5. Kaldjian EP, Gre tz JE, Anderson AO, Shi Y, Shaw S. Spatial and molecular organization of lymph node T cell cortex: a labyrinthine cavity bounded by an epithelium-like monolayer of fibroblastic reticular cells anchored to basement membrane-like extracellular matrix. Int Immunol. 2001;13:1243–53.
6. Katakai T, Hara T, Lee J-H, Gonda H, Sugai M, Shimizu A, A novel reticular stromal structure in lymph node cortex: an immuno-platform for interactions among dendritic cells, T cells and B cells. Int Immunol. 2004;16:113–42.
7. Cukierman E, Pankov R, Yamada KM. Cell interactions with three-dimensional matrices. Curr Opin Cell Biol. 2002;14:633–9.
8. Gould VE, Warren WH, Faber LP, Kuhn C, Franke WW. Malignant cells of epithelial phenotype limited to thoracic lymph nodes. Eur J Cancer. 1990;26:1121–7.
9. Chan AC, Chan KW, Chan JK, Au WY, Ho WK, Ng WM. Development of follicular dendritic cell sarcoma in hyaline-vascular Castleman’s disease of the nasopharynx: tracing its evolution by sequential biopsies. Histopathology. 2001;38:510–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

10. Schuerfeld K, Lazzi S, De Santi MM, Gozzetti A, Leoncini L, Pileri SA. Cytokeratin-positive interstitial cell neoplasm: a case report and classification issues. Histopathology. 2003;43:491–4.
11. Lucioni M, Boveri E, Rosso R, et al. Lymph node reticulum cell neoplasm with progression into cytokeratin-positive interstitial reticulum cell (CIRC) sarcoma: a case study. Histopathology. 2003;43:583–91.
12. Karim Z, Saravana R, Shenjere P, Reid F. Fibroblastic reticular cell tumor of spleen: a case report. Int J Surg Pathol. 2011;19:477–50.
13. Goto N, Tsumui H, Takami T, et al. Cytokeratin-positive fibroblastic reticular cell tumor with follicular dendritic cell features: a case report and review of the literature. Am J Surg Pathol. 2015;39:73–80.
14. Bosmuller H, Klenke J, Bonzheim I, et al. Cytokeratin-positive interstitial reticulum cell tumor: recognition of a potential “in situ” pattern. Hum Pathol. 2016;49:15–21.
15. Franke WW, Moll R. Cytoskeletal components of lymphoid organs. I. Synthesis of cytokeratins 8 and 18 and desmin in subpopulations of extrafollicular reticulum cells of human lymph nodes, tonsils, and spleen. Differentiation. 1987;36:145–63.
16. Doglioni C, Dell’Orto P, Zanetti G, Iuzzolino P, Coggi G, Viale G. Cytokeratin-immunoreactive cells of human lymph nodes and spleen in normal and pathological conditions. An immunocytochemical study. Virchows Arch A Pathol Anat Histopathol. 1990;416:79–90.
17. Tykociński M, Schinella RA, Greco MA. Fibroblastic reticulum cells in human lymph nodes. An ultrastructural study. Arch Pathol Lab Med. 1983;107:418–22.
18. Thomazy VA, Vega F, Medeiros LJ, Davies PJ, Jones D. Phenotypic modulation of the stromal reticular network in normal and neoplastic lymph nodes: tissue transglutaminase reveals coordinate regulation of multiple cell types. Am J Pathol. 2003;163:165–74.
19. Ohe R, Aung NY, Meng H, et al. Localization of collagen modifying enzymes on fibroblastic reticular cells and follicular dendritic cells in non-neoplastic and neoplastic lymphoid tissues. Leuk Lymphoma. 2016;57:1687–96.
20. Gould VE, Bloom KB, Franke WW, Warren WH, Moll R. Increased numbers of cytokeratin-positive interstitial reticulum cells (CIRC) in reactive, inflammatory and neoplastic lymphadenopathies: hyperplasia or induced expression? Virchows Arch. 1995;425:617–29.
21. Pileri SA, Grogan TM, Harris NL, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the international lymphoma study group based on 61 cases. Histopathology. 2002;41:1–29.
22. Gaetner EM, Tsikos M, Derringer GA, Neuhauser TS, Arciero C, Andrikia JA. Interdigitating dendritic cell sarcoma. A report of four cases and review of the literature. Am J Clin Pathol. 2001;115:589–97.
23. Chan AC, Chan KW, Chan JK, Au WY, Ho WK, Ng WM. Phenotypic expression of follicular dendritic cell sarcoma in hyaline-vascular Castleman’s disease of the nasopharynx: tracing its evolution by sequential biopsies. Histopathology. 2001;38:510–8.